Sociedad Americana de Hirudoterapia

LMWH for perioperative anticoagulation in patients on chronic warfarin therapy.

Research article published in The Annals of pharmacotherapy (2004)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewEnsayos clínicosHeuts et al. · The Annals of pharmacotherapy, 2004

Abstract

OBJECTIVE: To review current data regarding low-molecular-weight heparin (LMWH) use for perioperative anticoagulation in patients receiving chronic warfarin therapy. DATA SOURCES: Data were obtained from the Sixth American College of Chest Physicians Consensus Conference on Antithrombotic Therapy guidelines and a MEDLINE search (1996-January 2003). Search terms included heparin, low-molecular-weight heparin, warfarin, perioperative care, and anticoagulants. DATA SYNTHESIS: Heparin is the most common agent used as bridge therapy for perioperative anticoagulation in patients on chronic warfarin therapy; LMWHs are also used. Studies that evaluated enoxaparin and/or dalteparin were reviewed. CONCLUSIONS: Although published studies demonstrate efficacy and safety of LMWHs, more data are needed to support their use as bridge therapy.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsClinical Trials as TopicFibrinolytic AgentsHeparin, Low-Molecular-WeightHumansPerioperative CareThromboembolismWarfarin

Resumen

LMWH for perioperative anticoagulation in patients on chronic warfarin therapy.

Por qué esto importa para la hirudoterapia

This review examined current data on low-molecular-weight heparin (LMWH) use for perioperative anticoagulation bridging in patients on chronic warfarin therapy, drawing on ACCP consensus guidelines and a MEDLINE search (1996–2003) covering enoxaparin and dalteparin. It concluded that while published studies demonstrate efficacy and safety of LMWHs, more data are needed to support their use as bridge therapy. For ASH's domain, the article is relevant only insofar as it concerns anticoagulation management broadly; it does not address leeches, hirudotherapy, or leech-derived anticoagulants. The relevance to hirudotherapy is essentially nil — this is a conventional heparin/warfarin pharmacology review with no leech secretome content. Any interest would be purely contextual, as background on anticoagulant bridging strategies unrelated to leech therapy.

Citación

LMWH for perioperative anticoagulation in patients on chronic warfarin therapy.

Heuts et al. · The Annals of pharmacotherapy, 2004

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.